For Breast Cancer Awareness Month, BioSpace gathered examples of recent breakthroughs in breast cancer treatment.
The European Commission approved Astellas Pharma’s oral once-daily therapy Xospata as a monotherapy for treating adults with relapsed or refractory acute myeloid leukemia with a FLT3 mutation.
U.S. federal agents executed a warrant to search the Clio Laboratories in Georgia as part of a nationwide crackdown into genetic testing fraud against federal health insurance programs.
In the halls of MD Anderson Cancer Center, Vitrakvi is known for having a “Lazarus effect” in some patients because the drug can reverse late-stage cancer that has defied all other treatment options.
Roche Holding AG priced the company’s personalized cancer treatment Rozlytrek at about $17,050 per month, nearly half of the monthly price of a rival drug from Bayer AG and Eli Lilly and Co. that was approved during 2018.
The EMA recommended approving Vitrakvi to tackle tumors with a specific genetic mutation regardless of where the disease started.
The U.S. Food and Drug Administration lifted a partial clinical hold placed on AbbVie’s Phase III CANOVA trial evaluating venetoclax for the treatment of relapsed/refractory multiple myeloma.
Columbia Care Announces Launch of Pioneering Research Study to Identify Genetic Factors Affecting the Efficacy and Safety of Medical Cannabis
Columbia Care Inc. announced the initiation of a research study designed to optimize the use of the company’s precisely manufactured, pharmaceutical-quality medical cannabis products through the identification of genetic factors affecting their safety and efficacy.
The advent of increasingly more mainstream and affordable genetic testing enables powerful genetic research – but that power is directly associated with the strength and diversity of the database of genetic information available.
Swiss drugmaker Roche’s push into personalized cancer medicines hit a milestone with Japanese approval of a new drug, Rozlytrek, that targets patients who must be identified via genetic profiling.